- Home
- RFM vs MNOV Comparison
RFM vs MNOV Comparison
Compare RFM & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFM | MNOV |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.2M | 72.7M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | RFM | MNOV |
|---|---|---|
| Price | $13.95 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 20.7K | ★ 80.3K |
| Earning Date | 01-01-0001 | 02-18-2026 |
| Dividend Yield | ★ 9.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,917.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.89 | $1.13 |
| 52 Week High | $16.41 | $2.20 |
Technical Indicators
Market Signals| Indicator | RFM | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 35.86 |
| Support Level | $13.86 | $1.23 |
| Resistance Level | $14.17 | $1.51 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 28.75 | 18.18 |
Price Performance
Historical ComparisonAbout RFM RiverNorth Flexible Municipal Income Fund Inc.
RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.